Answers are grounded in this paper and cite their sources.
Imaging of prostate cancer (PCa) plays an important role in guiding biopsy at initial diagnosis, in accurately evaluating the extent of disease, in assessing sites of recurrent disease, and in monitoring response to treatment. A variety of PET radiopharmaceuticals for PCa are in clinical trials or
No takes yet. Share an insight, caveat, or question.
Andrei H. Iagaru (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: